[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-operative-pulmonary-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-operative-pulmonary-complications":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100608571","phase-4-risk-of-acute-complications-with-rocuronium-vs-cisatracurium-in-patients-with-chronic-kidney-disease-100608571",false,"NCT07203287","Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* The subject is able and willing to provide and sign informed consent\n* The subject must be between 18 and 80 years of age\n* The subject should have chronic kidney disease as defined by glomerular filtration rate\n* The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade\n\nExclusion Criteria:\n\n* Any patient under the age of 18\n* Any patient over the age of 80\n* Any patient with end stage renal disease\n* Any patient requiring dialysis\n* Patients presenting for Renal Transplantation\n* Pregnant Female\n* Any patient in the correctional system\n* Urgent or Emergent procedure\n* The surgery requires intubation post-operatively\n* Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine",true,"ALL","18 Years","80 Years",{"count":20,"type":21},490,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is\n\n\"The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex.\"",[27,28,29],"Post Operative Pulmonary Complications","Neuromuscular Blockade","General Anesthesia","RECRUITING","2026-02-19",{"date":33,"type":34},"2026-02-23","ACTUAL",{"date":36,"type":34},"2025-08-26",{"date":38,"type":21},"2027-08-26",{"name":40,"class":41},"The University of Texas Medical Branch, Galveston","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100479711","a-rct-on-the-preventive-effect-of-hfnc-on-postoperative-pulmonary-complications-in-patients-with-gynecologic-neoplasms-100479711","NCT05526534","A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms","A Randomized Controlled Trial on the Preventive Effect of Heated Humidified High Flow Nasal Cannula Oxygen Therapy on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms","Inclusion Criteria:\n\n* Patients with gynecologic Neoplasms, including benign gynecologic tumors and malignant gynecologic tumors, who are 18 to 90 years old and are scheduled for surgical treatment in our center shall receive plain chest CT scan within 1 week before surgery, and the estimated surgical time shall be ≥2 hours, and at least one of the following conditions shall be met:\n\n  1. Assess respiratory risk in surgical patients in Catalonia (ARRSPC) ≥45 points;\n  2. BMI≥30;\n  3. Moderate to severe asthma;\n  4. Moderate to severe chronic obstructive pulmonary disease (COPD);\n  5. Smoking history ≥20 packs\u002Fyear\n\nExclusion Criteria:\n\n1. Patients with lung metastasis of malignant tumor or primary lung malignant tumor;\n2. previous lung surgery or radiotherapy;\n3. the surgery involved segmental bowel resection.","FEMALE","90 Years",{"count":53,"type":21},200,[55],"NA","Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.",[58,59,60],"Gynecologic Surgery","High-flow Nasal Cannula","Post-operative Pulmonary Complications","2025-05-20",{"date":63,"type":34},"2025-05-23",{"date":65,"type":34},"2022-11-01",{"date":67,"type":21},"2025-12-31",{"name":69,"class":41},"Sichuan Cancer Hospital and Research Institute"]